Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Investor Presentation (March 2021)
16 slides from Atomo Diagnostics's investor presentation, Mar 10, 2021
Slide 1: Market Update
For personal use only This announcement was authorised by John Kelly, Managing Director Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia MARKET UPDATE 10 March 2021 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Disclaimer
For personal use only DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (ACN 142 925 684) (the Company). It contains completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this general background information only which is current at
Slide 3: Introduction
For personal use only INTRODUCTION Atomo Diagnostics Limited (“Atomo”) (ASX: AT1) is a medical company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market • Headquartered in Australia, Atomo develops and manufactures innovative patented devices that simpl
Slide 4: Patent Protected Unique Solutions
For personal use only PAT E N T P R O T E C T E D U N I Q U E S O L U T I O N S Traditional ‘bits in a box’ kits Atomo’s fully integrated user-friendly solutions* Standard lateral flow ‘bits in a box’ test kits Atomo has developed a range of The test process can be completed typically contain multip
Slide 5: Company Timeline
For personal use only C O M PA N Y T I M E L I N E Atomo HIV Self Test Viatris (ex: Mylan) Atomo pivots to Atomo secures first Pre‐commercialisation Atomo HIV Self approved by the launches the Atomo COVID‐192: NG/ large US contract – Test approved for CE marking Australian TGA as HIV Self Test in Eu
Slide 6: Key Financial Metrics for HFY - Strong top-line growth
For personal use only K E Y F I N A N C I A L M E T R I C S F O R 1 H F Y 2 11 - S t r o n g t o p - l i n e g r o w t h Revenue Gross Profit GP Margin Drivers Revenue: $4.58m $2.52m 55% • COVID-19: Sales to NG Biotech & direct to the Australian market • HIV: Viatris (ex: Mylan) sales into 388% 278%
Slide 7: Underlying P/L & Cash Flow - Scale benefits materialising
For personal use only U N D E R LY I N G P / L & C A S H F L O W – S c a l e b e n e f i t s m a t e r i a l i s i n g • Significant revenue growth of 389% generated by: • $2.61 million from continued customer demand for COVID-19 point of care antibody testing devices, including sales of Atomo devic
Slide 8: Key Medium Term Strategic Focus
For personal use only K E Y M E D I U M T E R M S T R AT E G I C F O C U S Leveraging existing COVID business HIV business platforms Commercialising new Atomo Anticipating strong growth - and OEM products: COVID – an ongoing test upgraded facility ready to market • Neutralizing COVID-19 support larg
Slide 9: COVID-19 - An Ongoing Test Market - Broad Trends
For personal use only COVID-19 – AN ONGOING TEST MARKET – BROAD TRENDS * *Source: Atomo. The COVID-19 Rapid Testing Landscape is conceptual in nature and seeks to broadly outline trends in testing demand experienced by Atomo, Atomo customers and through dialogue with industry participants. The chart
Slide 10: Atomo's COVID Business - Emerging Global Coverage
For personal use only AT O M O ’ S C O V I D B U S I N E S S – E M E R G I N G G L O B A L C O V E R A G E * • 1.9m units sold to NG Biotech for France • NG Biotech Self test CE Mark target mid CY21 • Atomo in discussions with • Other partner discussions in progress large Chinese global player • Con
Slide 11: HIV Self-Testing: A Global Opportunity
For personal use only HIV SELF-TESTING: A GLOBAL OPPORTUNITY Global Health Markets Private Sector Markets Strategic Companion Dx Partnership with Viatris (ex: Mylan) Atomo has partnered with the leading global HIV drug business through an exclusive agreement covering more than 100 countries With
Slide 12: Leveraging Existing Platforms
For personal use only L E V E R A G I N G E X I S T I N G P L AT F O R M S Atomo has developed innovative integrated rapid test platforms which offer improved functionality and reliability for a broad range of clinical applications The company is focused on commercialising a range of RDT products on
Slide 13: Growing Atomo's Capabilities and Operations
For personal use only G R O W I N G AT O M O ’ S C A PA B I L I T I E S A N D O P E R AT I O N S Atomo is expanding its development and manufacturing Next gen blister manufacturing capabilities to expedite the commercialisation of finished Completed redesign and commenced build for products addition
Slide 14: International Expansion
For personal use only I N T E R N AT I O N A L E X PA N S I O N * US MARKET NEW MARKET ENTRY Increased focus on securing additional US partners (both OEM The opportunity for Atomo’s products is global with a customers and channel partners for Atomo products) focus on entering new large markets Launc
Slide 15: Investment Case
For personal use only INVESTMENT CASE A proven innovator – commercialised the world’s first fully integrated, blood-based rapid tests Emerging market participant with more than 3.5m units sold globally to date and a further 2m units contracted ‘Best in class’ solutions based on Atomo’s award winning
Slide 16: John Kelly, Managing Director
For personal use only John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com
Atomo Diagnostics — Investor Presentation (March 2021) on 6ix